194 related articles for article (PubMed ID: 20535969)
21. Current status of second-line therapy for metastatic colorectal cancer.
Rothenberg ML
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
23. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab in colon cancer.
Giuliani F; Colucci G
Int J Biol Markers; 2007; 22(1 Suppl 4):S62-70. PubMed ID: 17520583
[TBL] [Abstract][Full Text] [Related]
25. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
[No Abstract] [Full Text] [Related]
26. [Biotherapy in colorectal cancer].
Des Guetz G
J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
28. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Okines A; Cunningham D
Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
[TBL] [Abstract][Full Text] [Related]
29. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
31. Progress in the development of novel treatments for colorectal cancer.
Hoff PM; Pazdur R
Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
[TBL] [Abstract][Full Text] [Related]
32. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
33. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
34. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Cohen MS; Al-Kasspooles MF; Williamson SK; Henry D; Broward M; Roby KF
Ann Surg Oncol; 2010 Jan; 17(1):296-303. PubMed ID: 19707832
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
36. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
Chua W; Kho PS; Moore MM; Charles KA; Clarke SJ
Crit Rev Oncol Hematol; 2011 Sep; 79(3):224-50. PubMed ID: 20719530
[TBL] [Abstract][Full Text] [Related]
37. Metastatic colorectal cancer: is there one standard approach?
Saltz LB
Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
[TBL] [Abstract][Full Text] [Related]
38. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
39. Current therapies for advanced colorectal cancer.
Aggarwal S; Chu E
Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340
[TBL] [Abstract][Full Text] [Related]
40. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
